[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649212":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":41,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":26,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Period 1 : Treatment A(AD-236A), Period 2 : Treatment C(AD-236A+AD-236B)",[13,14],"Drug: Treatment A(AD-236A)","Drug: Treatment C(AD-236A+AD-236B)",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B","Period 1 : Treatment B(AD-236B), Period 2 : Treatment C(AD-236A+AD-236B)",[19,14],"Drug: Treatment B(AD-236B)",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Treatment A(AD-236A)","AD-236A Oral Tablet",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Treatment B(AD-236B)","AD-236B Oral Tablet",[16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Treatment C(AD-236A+AD-236B)","AD-236A+AD-236B Oral Tablet",[9,16],[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Heeyoung Hong","CONTACT","821094710619","hyhong@addpharma.co.kr",[42],{"facility":43,"status":26,"city":44,"state":26,"zip":45,"country":46,"countryCode":26,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"H+ Yangji Hospital, Seoul,","Seoul","08779","South Korea",{"type":48,"coordinates":49},"Point",[50,51],126.9784,37.566,{"lat":51,"lon":50},[54],{"name":55,"role":38,"phone":56,"phoneExt":26,"email":57},"Seunghyun Kang","+82-70-4665-9174","m4222@newyjh.com",{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100649212","phase-1-a-study-to-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-236a-and-ad-236b-100649212",false,"NCT07730567","A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and ≤55 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","55 Years",{"count":72,"type":73},44,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers",[79,80],"Hyperlipidemia","Diabete Type 2","NOT_YET_RECRUITING","2026-07-23",{"date":84,"type":85},"2026-07-28","ACTUAL",{"date":87,"type":73},"2026-07-29",{"date":89,"type":73},"2026-09-26",{"name":5,"class":6},1]